<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01195298</url>
  </required_header>
  <id_info>
    <org_study_id>ML22373</org_study_id>
    <nct_id>NCT01195298</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Capecitabine in Treatment of Elderly Patients With Metastatic Breast Cancer</brief_title>
  <official_title>Phase II Clinical Study of Bevacizumab in Combination With Capecitabine as First-line Treatment in Elderly Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>South Eastern European Research Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>South Eastern European Research Oncology Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-arm, multicenter study of capecitabine and bevacizumab
      administered as first-line treatment of previously untreated elderly patients, older than 70
      years, with metastatic or locally recurrent breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2010</start_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to treatment progression</measure>
    <time_frame>average 5 years</time_frame>
    <description>followed until death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate in patients with measurable disease at baseline</measure>
    <time_frame>average 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety and tolerability</measure>
    <time_frame>average 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit (complete response, partial response and stable disease) in patients with measurable disease at baseline</measure>
    <time_frame>average 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>average 5 years</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Metastasis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine and Bevacizumab</intervention_name>
    <description>Drugs will be administered in 3-week cycles as follows:
Bevacizumab 15mg/kg via i.v. infusion on day 1
Capecitabine 1000 mg/m2 tablets twice-daily, on days 1 through 14.</description>
    <other_name>Bevacizumab (Avastin )</other_name>
    <other_name>Capecitabine (Xeloda)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent obtained prior to initiation of any study specific procedures
             and treatment as confirmation of the patient's awareness and willingness to comply
             with the Protocol code: ML22373 Protocol SEEROG: version 1.2. Date: October 15, 2009 3
             study requirements;

          -  Age ≥70 years;

          -  Pathologically confirmed and documented metastatic breast cancer or locally recurrent
             breast cancer not amenable to curative treatment. Complete radiology and tumor
             measurement workup must be completed within 4 weeks prior to first study treatment;

          -  Measurable disease according to RECIST criteria;

          -  HER2 negative disease;

          -  No prior treatment for metastatic or locally recurrent disease;

          -  Prior radiotherapy is allowed if delivered at least 2 weeks before enrolment in the
             study and for the relief of metastatic bone pain, and provided that no more than 30%
             of marrow bearing bone was irradiated and that target lesions were not included in the
             radiotherapy field;

          -  Not suitable for aggressive chemotherapy regimen in the opinion of the investigator;

          -  Performance status ECOG 0 - 2.

        Exclusion Criteria:

          -  Any prior neoadjuvant or adjuvant treatment with anthracyclines completed less than 6
             months prior to enrolment. The maximum cumulative dose received must not have exceeded
             360 mg/m2 for doxorubicin or 720 mg/m2 for epirubicin. Prior anti-epidermal growth
             factor therapy is allowed;

          -  Concurrent hormonal therapy; however previous hormonal therapy is allowed for
             adjuvant, locally recurrent, or metastatic breast cancer if completed within ≥1 months
             prior to enrolment;

          -  History or clinical evidence of brain metastases. If there is any clinical suspicion
             of brain metastasis, a computerized tomography (CT) scan or magnetic resonance imaging
             (MRI) of the brain must be conducted within 4 weeks prior to enrolment;

          -  Other malignancy (including primary brain tumors) within the Protocol code: ML22373
             Protocol SEEROG: version 1.2. Date: October 15, 2009 4 last 5 years, which could
             affect the diagnosis or assessment of breast cancer, except for adequately treated
             carcinoma in situ of the cervix, squamous carcinoma of the skin, or adequately
             controlled limited basal cell skin cancer;

          -  Life expectancy &lt; 12 weeks;

          -  Any of the following abnormal values:

               -  Inadequate bone marrow function: hemoglobin (Hb) &lt; 8.0 g/dL, absolute neutrophil
                  count (ANC) &lt; 1.5 x 109/L, or platelet count &lt; 100 x 109/L;

               -  Inadequate liver function: AST/SGOT or ALT/SGPT &gt; 2.5 x upper limit of normal
                  (ULN) or &gt; 5 x ULN in patients with liver metastases), serum alkaline phosphatase
                  &gt; 2.5 ULN or &gt; 5 x ULN in patients with liver metastases, or &gt; 10 x ULN in
                  patients with bone metastases or total bilirubin &gt; 2 x ULN;

               -  Moderate or severe renal impairment: creatinine clearance ≤50 mL/min (calculated
                  according to the cockcroft and Gault formula; see Appendix 1), or serum
                  creatinine &gt; 1.5 x ULN;

          -  Chronic daily treatment with aspirin (&gt; 325 mg/day) or clopidogrel (&gt; 75 mg / day);

          -  Chronic daily treatment with corticosteroids (dose of &gt; 10 mg/day methylprednisolone
             equivalent) (excluding inhaled steroids);

          -  Requirement for concurrent use of the antiviral agents sorivudine or brivudine;

          -  Major surgical procedure, open biopsy or significant traumatic injury within 28 days
             prior to enrolment, or anticipation of the need for major surgery during the course of
             the study treatment;

          -  Minor surgical procedures, within 24 hours prior to enrolment;

          -  Current or recent (within the 30 days prior to starting study treatment) treatment
             with another investigational drug or participation in another investigational study.

          -  Uncontrolled hypertension (systolic &gt; 150 mm Hg and/or diastolic &gt; 100 mm Hg) or
             clinically significant (i.e. active) cardiovascular disease, including:

          -  Cerebrovascular accident/stroke (≤ 6 months prior to enrolment)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eduard Vrdoljak, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Hospital Split, Center of oncology, Croatia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Damir Vrbanec, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Hospital Zagreb, Croatia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katarina Petrakova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masaryk Memorial Cancer Institue, Brno, Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gyorgy Bodoky, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FOVAROSI SZENT LASZLO KORHAZ-RENDELOINTEZET, ONKOLOGIAI OSZTALY, Budapest, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tamas Pinter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Petz, Aladar Korhaz, Onkoradiologiai Osztaly, Gyor, Hungary</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vladimir Todorović, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oncology clinic, Clinical Center of Montenegro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marek Wojtukiewicz, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology Medical University, Bialystok, Poland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tadeusz Pienkowski, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Centre and Institute of Oncology Warsaw</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniela Grecea, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>&quot;Prof Dr. I Chiricuta&quot; Cluj Napoca Oncology Institute - Breast Cancer Center, Cluj Napoca, Romania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Hospital Split, Center of oncology</name>
      <address>
        <city>Split</city>
        <zip>21000</zip>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduard Vrdoljak, PhD MD</last_name>
      <phone>00385-21-556-129</phone>
      <email>eduard.vrdoljak@st.htnet.hr</email>
    </contact>
    <investigator>
      <last_name>Eduard Vrdoljak, PhD MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Croatia</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2010</study_first_submitted>
  <study_first_submitted_qc>September 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2010</study_first_posted>
  <last_update_submitted>September 3, 2010</last_update_submitted>
  <last_update_submitted_qc>September 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 6, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. dr. sc. Eduard Vrdoljak</name_title>
    <organization>Clinical Hospitl Split, Center of oncology</organization>
  </responsible_party>
  <keyword>metastatic breast cancer</keyword>
  <keyword>elderly patients</keyword>
  <keyword>chemoimmunotherapy</keyword>
  <keyword>Triple negative metastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

